Which has stronger earnings & valuation, ANAB or CGON?

AnaptysBio has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 5.81 -$13.23M $5.37 8.49 CG Oncology $4.04M 1,369.09 -$160.99M -$2.69 N/A

Is ANAB or CGON more profitable?

AnaptysBio has a net margin of 82.37% compared to CG Oncology's net margin of -3,602.68%. AnaptysBio's return on equity of 112.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio 82.37% 112.00% 2.20% CG Oncology -3,602.68% -25.20% -23.98%

Does the media refer more to ANAB or CGON?

In the previous week, CG Oncology had 4 more articles in the media than AnaptysBio. MarketBeat recorded 9 mentions for CG Oncology and 5 mentions for AnaptysBio. CG Oncology's average media sentiment score of 0.55 beat AnaptysBio's score of 0.46 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer PTCT or ANAB?

In the previous week, PTC Therapeutics had 14 more articles in the media than AnaptysBio. MarketBeat recorded 19 mentions for PTC Therapeutics and 5 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.46 beat PTC Therapeutics' score of 0.43 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ANAB or ORKA?

In the previous week, Oruka Therapeutics had 1 more articles in the media than AnaptysBio. MarketBeat recorded 6 mentions for Oruka Therapeutics and 5 mentions for AnaptysBio. Oruka Therapeutics' average media sentiment score of 0.79 beat AnaptysBio's score of 0.46 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TVTX or ANAB?

In the previous week, Travere Therapeutics and Travere Therapeutics both had 5 articles in the media. Travere Therapeutics' average media sentiment score of 0.91 beat AnaptysBio's score of 0.46 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AnaptysBio (ANAB) Competitors

$46.69 +1.10 (+2.41%)

As of 11:01 AM Eastern

Compare

ANAB vs. CGON, PTCT, ORKA, TVTX, and COGT

Should you buy AnaptysBio stock or one of its competitors? AnaptysBio's main competitors and comparable companies include CG Oncology (CGON), PTC Therapeutics (PTCT), Oruka Therapeutics (ORKA), Travere Therapeutics (TVTX), and Cogent Biosciences (COGT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AnaptysBio compare to CG Oncology?

AnaptysBio (NASDAQ:ANAB) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, CG Oncology had 4 more articles in the media than AnaptysBio. MarketBeat recorded 9 mentions for CG Oncology and 5 mentions for AnaptysBio. CG Oncology's average media sentiment score of 0.55 beat AnaptysBio's score of 0.46 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

AnaptysBio has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	5.81	-$13.23M	$5.37	8.49
CG Oncology	$4.04M	1,369.09	-$160.99M	-$2.69	N/A

AnaptysBio currently has a consensus target price of $77.79, indicating a potential upside of 70.62%. CG Oncology has a consensus target price of $87.50, indicating a potential upside of 40.22%. Given AnaptysBio's stronger consensus rating and higher possible upside, research analysts plainly believe AnaptysBio is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

AnaptysBio has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

AnaptysBio has a net margin of 82.37% compared to CG Oncology's net margin of -3,602.68%. AnaptysBio's return on equity of 112.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	82.37%	112.00%	2.20%
CG Oncology	-3,602.68%	-25.20%	-23.98%

26.6% of CG Oncology shares are held by institutional investors. 31.5% of AnaptysBio shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AnaptysBio beats CG Oncology on 12 of the 16 factors compared between the two stocks.

How does AnaptysBio compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

In the previous week, PTC Therapeutics had 14 more articles in the media than AnaptysBio. MarketBeat recorded 19 mentions for PTC Therapeutics and 5 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.46 beat PTC Therapeutics' score of 0.43 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

PTC Therapeutics presently has a consensus price target of $98.25, indicating a potential upside of 63.97%. AnaptysBio has a consensus price target of $77.79, indicating a potential upside of 70.62%. Given AnaptysBio's stronger consensus rating and higher possible upside, analysts clearly believe AnaptysBio is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

PTC Therapeutics has higher revenue and earnings than AnaptysBio. PTC Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	2.89	$682.64M	-$0.58	N/A
AnaptysBio	$234.60M	5.81	-$13.23M	$5.37	8.49

AnaptysBio has a net margin of 82.37% compared to PTC Therapeutics' net margin of -3.80%. AnaptysBio's return on equity of 112.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
AnaptysBio	82.37%	112.00%	2.20%

Summary

AnaptysBio beats PTC Therapeutics on 10 of the 14 factors compared between the two stocks.

How does AnaptysBio compare to Oruka Therapeutics?

AnaptysBio (NASDAQ:ANAB) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

56.4% of Oruka Therapeutics shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AnaptysBio has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	5.81	-$13.23M	$5.37	8.49
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

AnaptysBio has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market.

AnaptysBio has a net margin of 82.37% compared to Oruka Therapeutics' net margin of 0.00%. AnaptysBio's return on equity of 112.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	82.37%	112.00%	2.20%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, Oruka Therapeutics had 1 more articles in the media than AnaptysBio. MarketBeat recorded 6 mentions for Oruka Therapeutics and 5 mentions for AnaptysBio. Oruka Therapeutics' average media sentiment score of 0.79 beat AnaptysBio's score of 0.46 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio presently has a consensus target price of $77.79, suggesting a potential upside of 70.62%. Oruka Therapeutics has a consensus target price of $128.91, suggesting a potential upside of 64.87%. Given AnaptysBio's higher probable upside, analysts clearly believe AnaptysBio is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

AnaptysBio beats Oruka Therapeutics on 10 of the 14 factors compared between the two stocks.

How does AnaptysBio compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Travere Therapeutics currently has a consensus price target of $69.50, suggesting a potential upside of 34.17%. AnaptysBio has a consensus price target of $77.79, suggesting a potential upside of 70.62%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

AnaptysBio has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	9.95	-$25.55M	-$0.46	N/A
AnaptysBio	$234.60M	5.81	-$13.23M	$5.37	8.49

In the previous week, Travere Therapeutics and Travere Therapeutics both had 5 articles in the media. Travere Therapeutics' average media sentiment score of 0.91 beat AnaptysBio's score of 0.46 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AnaptysBio has a net margin of 82.37% compared to Travere Therapeutics' net margin of -7.35%. AnaptysBio's return on equity of 112.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
AnaptysBio	82.37%	112.00%	2.20%

Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Summary

AnaptysBio beats Travere Therapeutics on 8 of the 13 factors compared between the two stocks.

How does AnaptysBio compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, AnaptysBio had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for AnaptysBio and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat AnaptysBio's score of 0.46 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Very Positive
AnaptysBio	Neutral

Cogent Biosciences currently has a consensus target price of $51.56, indicating a potential upside of 83.54%. AnaptysBio has a consensus target price of $77.79, indicating a potential upside of 70.62%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cogent Biosciences is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

AnaptysBio has a net margin of 82.37% compared to Cogent Biosciences' net margin of 0.00%. AnaptysBio's return on equity of 112.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
AnaptysBio	82.37%	112.00%	2.20%

Cogent Biosciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
AnaptysBio	$234.60M	5.81	-$13.23M	$5.37	8.49

Summary

AnaptysBio beats Cogent Biosciences on 10 of the 14 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANAB vs. The Competition

Export

Metric	AnaptysBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.39B	$3.88B	$7.26B	$13.10B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	8.68	13.21	275.54	25.58
Price / Sales	5.96	1,131.68	557.67	80.26
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	34.89	17.16	10.81	6.02
Net Income	-$13.23M	-$22.65M	$3.49B	$380.34M
7 Day Performance	2.43%	-4.64%	-3.00%	-3.19%
1 Month Performance	-13.59%	-12.66%	-7.48%	-6.07%
1 Year Performance	46.81%	8.08%	3.18%	-3.77%

AnaptysBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANAB AnaptysBio	2.8561 of 5 stars	$46.69 +2.4%	$77.79 +66.6%	+40.4%	$1.39B	$234.60M	8.67	104
CGON CG Oncology	3.6727 of 5 stars	$62.38 -2.0%	$87.50 +40.3%	+45.3%	$5.64B	$4.04M	N/A	142	News Coverage
PTCT PTC Therapeutics	4.0386 of 5 stars	$63.23 -0.7%	$99.08 +56.7%	-9.3%	$5.32B	$1.73B	N/A	991
ORKA Oruka Therapeutics	2.66 of 5 stars	$79.50 -0.8%	$128.91 +62.1%	+206.6%	$5.31B	N/A	N/A	68	Analyst Forecast Insider Trade
TVTX Travere Therapeutics	3.1885 of 5 stars	$53.44 -4.5%	$69.50 +30.1%	+97.7%	$5.28B	$490.73M	N/A	497

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANAB) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Competitors

ANAB vs. CGON, PTCT, ORKA, TVTX, and COGT

How does AnaptysBio compare to CG Oncology?

Summary

How does AnaptysBio compare to PTC Therapeutics?

Summary

How does AnaptysBio compare to Oruka Therapeutics?

Summary

How does AnaptysBio compare to Travere Therapeutics?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Competitors

ANAB vs. CGON, PTCT, ORKA, TVTX, and COGT

How does AnaptysBio compare to CG Oncology?

Does the media refer more to ANAB or CGON?

Which has stronger earnings & valuation, ANAB or CGON?

Do analysts rate ANAB or CGON?

Which has more risk & volatility, ANAB or CGON?

Is ANAB or CGON more profitable?

Do institutionals & insiders hold more shares of ANAB or CGON?

Summary

How does AnaptysBio compare to PTC Therapeutics?

Does the media prefer PTCT or ANAB?

Which has more volatility and risk, PTCT or ANAB?

Do analysts recommend PTCT or ANAB?

Which has higher valuation and earnings, PTCT or ANAB?

Is PTCT or ANAB more profitable?

Summary

How does AnaptysBio compare to Oruka Therapeutics?

Do institutionals & insiders have more ownership in ANAB or ORKA?

Which has higher valuation & earnings, ANAB or ORKA?

Which has more volatility & risk, ANAB or ORKA?

Is ANAB or ORKA more profitable?

Does the media refer more to ANAB or ORKA?

Do analysts prefer ANAB or ORKA?

Summary

How does AnaptysBio compare to Travere Therapeutics?

Do analysts prefer TVTX or ANAB?

Which has better earnings and valuation, TVTX or ANAB?

Does the media favor TVTX or ANAB?

Is TVTX or ANAB more profitable?

Which has more risk and volatility, TVTX or ANAB?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Does the media favor COGT or ANAB?

Do analysts recommend COGT or ANAB?

Is COGT or ANAB more profitable?

Which has more risk & volatility, COGT or ANAB?

Which has better valuation & earnings, COGT or ANAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools